BioMarin Pharmaceutical Inc
BMRNHealthcare|Biotechnology|USA
$56.02
-0.20 (-0.35%)
DCF (FCF)
$37.55
Tangible Book
$29.52
Graham Number
$45.74
Earnings Power
$19.68
Upcoming Data Readouts (25)
Jun 2026
Est. completion
P2Idiopathic Short Stature
A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature
NCT06382155n=100
Aug 2026
Est. completion
P4Phenylketonuria
Rapid Drug Desensitization Study in Adults Experiencing Hypersensitivity Reactions to Palynziq
NCT06780332n=9
Aug 2026
Est. completion
P3Hypochondroplasia
Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia
NCT06455059n=80
Sep 2026
Est. completion
P1P2Duchenne Muscular Dystrophy
A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants With Duchenne Muscular Dystrophy
NCT06280209n=18
Mar 2027
Est. completion
P2Short Stature Homeobox- Containing Gene SHOX Deficiency
A Basket Study of Vosoritide in Children With Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment
NCT06668805n=54
Jul 2027
Est. completion
P1Claudication, Intermittent
The Effects of ATLAS Therapy on Nitric Oxide Bioavailability in Patients With Intermittent Claudication
NCT04800692n=10
Nov 2027
Est. completion
P1Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency
The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency
NCT05734196n=16
Dec 2027
Est. completion
P2Achondroplasia
A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasia
NCT04554940n=20
Dec 2027
Est. completion
P2Achondroplasia
A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)
NCT02724228n=30
Dec 2027
Est. completion
Feb 2028
Est. completion
Jun 2028
Est. completion
P2Hypochondroplasia
A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months
NCT07126262n=60
Sep 2028
Est. completion
P3Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency
ENERGY 2: Evaluation of the Efficacy and Safety of INZ-701 in Infants With ENPP1 Deficiency
NCT07473973n=12
Nov 2028
Est. completion
P1P2Hereditary Angioedema
A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema
NCT05121376n=44
Dec 2028
Est. completion
Phenylketonurias
Nutritional Impacts of Palynziq on Patients With Phenylketonuria (PKU)
NCT04404530n=45
Apr 2029
Est. completion
P1P2Hemophilia A With Inhibitor
Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors
NCT04684940n=10
Aug 2030
Est. completion
Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2
Cerliponase Alfa Observational Study in the US
NCT04476862n=35
Dec 2030
Est. completion
Jun 2031
Est. completion
P3Achondroplasia
An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia
NCT03424018n=119
Oct 2032
Est. completion
Phenylketonuria, Maternal
A Global, Multicenter Study to Assess Maternal, Fetal and Infant Outcomes of Exposure to Palynziq® (Pegvaliase) During Pregnancy and Breastfeeding
NCT05579548n=50
Awaiting Results (2)
Trials past primary completion date but still active — data readout may be imminent.
Apr 2025
P3
Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia A
NCT06224907Jan 2025
P3
Study to Evaluate the Safety and Efficacy of Pegvaliase in Adolescents (Ages 12-17) With Phenylketonuria
NCT05270837